Search Results
ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients
AVO achieves high rates of undetectable MRD in CLL
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLL
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
GLOW: Assessing ibrutinib plus venetoclax in CLL
First-line ibrutinib and venetoclax in CLL
Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up data
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
CAPTIVATE: Ibrutinib and venetoclax in CLL
What were the CLL highlights at ASH 2020?
